Form 4: Ocular Therapeutix CSO Receives Equity Grant

Ocular Therapeutix's Chief Strategy Officer, Sanjay Nayak, was granted 64,900 restricted stock units and options for 197,650 shares on January 2, 2026.

Summary

• Sanjay Nayak, Chief Strategy Officer of Ocular Therapeutix, Inc. (OCUL), received an equity grant on January 2, 2026.
• The grant included 64,900 Restricted Stock Units (RSUs) at a price of $0 per share.
• The RSUs will vest over three years, with 1/3 vesting on the one-year anniversary of the grant date and an additional 1/3 vesting at the end of each successive one-year period thereafter, subject to continued service.
• Additionally, 197,650 stock options were granted with an exercise price of $11.82 per share.
• These stock options will vest over four years, with 1/48 vesting monthly beginning on the one-month anniversary of the grant date, subject to continued service.
• Following these transactions, Nayak beneficially owns 342,760 shares of common stock and 197,650 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The filing reports a standard equity grant to a key executive, which is generally positive for executive retention and alignment with shareholder interests. It does not contain any negative news or significant risks.

Positives

• The grant of 64,900 Restricted Stock Units (RSUs) and 197,650 stock options aligns the Chief Strategy Officer's interests with long-term shareholder value.
• Equity compensation is a standard practice for executive retention and motivation.

Future Outlook

The vesting schedules for both the Restricted Stock Units (RSUs) and stock options indicate a commitment to the reporting person's continued service to Ocular Therapeutix over the next three to four years, aligning executive incentives with long-term company performance.

Industry Context

Equity grants, including Restricted Stock Units and stock options, are a common component of executive compensation packages across the biotechnology and pharmaceutical industries. This practice aims to incentivize long-term performance and retain key talent by aligning executive interests with shareholder value creation.

Comparison to Industry Standards

• This type of equity grant, with multi-year vesting schedules, is consistent with standard executive compensation practices observed in the biotechnology sector.
• Companies like Biogen Inc. and Vertex Pharmaceuticals often utilize similar structures to retain and motivate their senior leadership, linking compensation directly to company performance and tenure.
• The specific number of shares and exercise price would typically be benchmarked against peer companies of similar market capitalization and stage of development, though specific comparable data is not provided in this filing.

Stakeholder Impact

• Shareholders: Potentially positive, as executive compensation tied to equity can align management's interests with long-term shareholder value.
• Employees: May signal stability in executive leadership and a commitment to retaining key talent.

Next Steps

• The Restricted Stock Units will begin vesting on the one-year anniversary of the grant date (January 2, 2027), with subsequent vesting annually.
• The stock options will begin vesting monthly, starting one month after the grant date (February 2, 2026).

Key Dates

Keywords

Ocular Therapeutix, OCUL, Sanjay Nayak, Chief Strategy Officer, Restricted Stock Units, RSUs, Stock Options, Equity Grant, Insider Transaction, Compensation, Executive Compensation